Evidence map›Paper›PMID 41692695›Full record

ArticleBritish journal of clinical pharmacology2026

Pharmacokinetic-pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real-world data.

Charlotte M Thomas, Jessica Ruoheng Wei, David Baudry, Zehra Arkir, Bola Coker, Tejus Dasandi, Kingsley Powell, Monica Arenas-Hernandez, Jenny Leung, Krystal Rawstron and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Charlotte M ThomasKing's College London, London, UK.ORCID https://orcid.org/0000-0002-7866-6991
Jessica Ruoheng WeiKing's College London, London, UK.
David BaudryKing's College London, London, UK.
Zehra ArkirClinical Biochemistry, Barts Health, London, UK.
Bola CokerGuy's & St Thomas' Hospital, London, UK.
Tejus DasandiGuy's & St Thomas' Hospital, London, UK.
Kingsley PowellKing's College London, London, UK.
Monica Arenas-HernandezGuy's & St Thomas' Hospital, London, UK.
Jenny LeungGuy's & St Thomas' Hospital, London, UK.
Krystal RawstronGuy's & St Thomas' Hospital, London, UK.
Chioma NwaoguGuy's & St Thomas' Hospital, London, UK.
Richard WoolfGuy's & St Thomas' Hospital, London, UK.
Andrew E PinkKing's College London, London, UK.
Jonathan BarkerKing's College London, London, UK.
Joseph F StandingUniversity College London, London, UK.ORCID https://orcid.org/0000-0002-4561-7173
Catherine H SmithKing's College London, London, UK.
Satveer K MahilKing's College London, London, UK.ORCID https://orcid.org/0000-0003-4692-3794

Funding

British Skin FoundationKHP Skin Health ThemeKing's Health Partners Centre for Translational MedicineNational Institute for Health and Care Research (NIHR) Advanced Fellowship NIHR 302258National Psoriasis FoundationPsoriasis AssociationUK Medical Research Council fellowship MR/M008665/1
6 · The paper itself

Abstract

aimRisankizumab is a high-cost biologic treatment for chronic plaque psoriasis, an immune-mediated inflammatory disease presenting with painful red scaly skin lesions. Inter-individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic/pharmacodynamic (PK/PD) model to characterise the relationship between risankizumab exposure and treatment response.

methodsA sequential population PK/PD model was developed using real-world data (UK Biomarkers of Systemic Treatment Outcomes in Psoriasis study) comprising serial PK and Psoriasis Area and Severity Index (PASI) measures. Models were built using R (V4.3.1) and nlmixr2 (V2.1.1.9). One and two-compartment PK models were tested. A maximal effect turnover model was used to describe PASI, with drug effect on lesion development rate (K

resultsThe dataset (82 serum risankizumab concentrations; 101 PASI observations) comprised 50 patients with psoriasis (median weight 79.3 kg; age 47 years). PK data were described by a one-compartment model with first-order absorption/elimination. Absorption rate (K

conclusionsPharmacokinetic parameters were similar to risankizumab clinical trials. K

Indexed as

Antibodies, MonoclonalDermatologic AgentsModels, BiologicalPsoriasisAdultAgedChronic DiseaseDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalDermatologic Agentsrisankizumabexposure‐responseimmune‐mediated inflammatory diseasespharmacokinetics‐pharmacodynamicspsoriasisrisankizumab

Identifiers

PMID41692695
PMCPMC13304286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.